Literature DB >> 25139772

Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis.

Flavia Ballocca1, Fabrizio D'Ascenzo2, Claudio Moretti2, Pierluigi Omedè2, Enrico Cerrato2, Umberto Barbero2, Antonio Abbate3, Maria Tiziana Bertero4, Giuseppe Biondi Zoccai5, Fiorenzo Gaita2.   

Abstract

BACKGROUND: Cardiovascular disease represents an important cause of morbidity and mortality in patients with a diagnosis of systemic lupus erythematosus (SLE), due to a complex interplay between traditional risk factors and disregulation of autoimmunity but uncertainty is still present about the most important predictors of cardiovascular events.
OBJECTIVES: The aim of our work was to perform a collaborative systematic review on the main predictors of cardiovascular events in SLE patients.
METHODS: PubMed and Cochrane were systematically searched for eligible studies on SLE and cardiovascular events between January 2008 and December 2012. Study features, patient characteristics and incidence of stent thrombosis were abstracted and pooled, when appropriate, with random-effect methods (point estimate - 95% confidence intervals) and consistency of predictors was formally appraised.
RESULTS: A total of 17,187 patients was included; of those, 93.1% were female and the median age was 39 years. After a median follow-up period of 8 years, cardiovascular events presented in 25.4%, including acute myocardial infarction (4.1%) and stroke (7.3%). The most important predictors may be divided into traditional risk factors, such as male gender (OR 6.2, CI 95% 1.49-25), hyperlipidaemia (OR 3.9, CI 95% 1.57-9.71), familiar history of cardiac disease (OR 3.6, CI 95% 1.15-11.32) and hypertension (OR 3.5, CI 95% 1.65-7.54), and SLE-related features, such as the presence of auto-antibodies (OR 5.8 and 5.0, CI 95% 3.28-7.78) and neurological disorders (OR 5.2, CI 95% 2.0-13.9). A low correlation was shown for the importance of organ damage and SLE activity (respectively OR 1.4, CI 95% 1.09-4.44 and OR 1.2, CI 95% 1.2-1.2), as well as for age at diagnosis (OR 1.1, CI 95% 1.07-1.17).
CONCLUSIONS: Cardiovascular events in SLE patients are caused by a multifactorial mechanism, including both traditional and disease-specific risk factors. A global valuation with an individual risk stratification based on both these features is important to correctly manage these patients in order to reduce negative outcomes. © The European Society of Cardiology 2014.

Entities:  

Keywords:  Systemic lupus erythematosus; cardiovascular events; predictors

Mesh:

Year:  2014        PMID: 25139772     DOI: 10.1177/2047487314546826

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  25 in total

1.  Comparison of non-invasive assessment of arrhythmias, conduction disturbances and cardiac autonomic tone in systemic sclerosis and systemic lupus erythematosus.

Authors:  Piotr Bienias; Michał Ciurzyński; Bartłomiej Kisiel; Anna Chrzanowska; Katarzyna Ciesielska; Maria Siwicka; Agnieszka Kalińska-Bienias; Marek Saracyn; Monika Lisicka; Joanna Radochońska; Piotr Pruszczyk
Journal:  Rheumatol Int       Date:  2018-11-12       Impact factor: 2.631

Review 2.  Magnetic resonance imaging for characterizing myocardial diseases.

Authors:  Maythem Saeed; Hui Liu; Chang-Hong Liang; Mark W Wilson
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-31       Impact factor: 2.357

3.  Cardiac manifestations of Han Chinese patients with systemic lupus erythematosus: a retrospective study.

Authors:  Ertao Jia; Hongling Geng; Qingping Liu; Yuya Xiao; Yanying Zhang; Jingjing Xie; Luhe Zhang; Xia Qiu; Li Zhong; Min Xiao; Jianyong Zhang
Journal:  Ir J Med Sci       Date:  2018-11-20       Impact factor: 1.568

Review 4.  Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases.

Authors:  Elena Bartoloni; Alessia Alunno; Roberto Gerli
Journal:  Nat Rev Cardiol       Date:  2017-08-24       Impact factor: 32.419

Review 5.  Role of Inflammatory Diseases in Hypertension.

Authors:  E Bartoloni; A Alunno; V Valentini; F Luccioli; E Valentini; G La Paglia; O Bistoni; Roberto Gerli
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-06-09

6.  Influence of autoimmunity and inflammation on endothelial function and thrombosis in systemic lupus erythematosus patients.

Authors:  Kamil Bugała; Adam Mazurek; Krzysztof Gryga; Monika Komar; Grzegorz Kopeć; Jacek Musiał; Piotr Podolec; Carlo Perricone; Wojciech Płazak
Journal:  Clin Rheumatol       Date:  2018-04-20       Impact factor: 2.980

Review 7.  Innate Immune Dysregulation in the Development of Cardiovascular Disease in Lupus.

Authors:  Gantsetseg Tumurkhuu; Erica Montano; Caroline Jefferies
Journal:  Curr Rheumatol Rep       Date:  2019-07-23       Impact factor: 4.592

Review 8.  Cytokine Circuits in Cardiovascular Disease.

Authors:  Jesse W Williams; Li-Hao Huang; Gwendalyn J Randolph
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

Review 9.  Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases.

Authors:  Nathalie Burg; Jane E Salmon; Timothy Hla
Journal:  Nat Rev Rheumatol       Date:  2022-05-04       Impact factor: 20.543

Review 10.  Update on cardiovascular disease in lupus.

Authors:  Laura B Lewandowski; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.